Synergistic action of doxorubicin and sulindac in human cervix carcinoma cells - Studies on possible mechanisms

Medical Science Monitor

Volumn 16, Issue 1, 2010, Pages

  Gruber, Beata Maria ^a   Bubko, Irena ^a   Krzysztoń Russjan, Jolanta ^a   Anuszewska, Elzbieta Lidia ^a  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Anthracyclines; Apoptosis; MDR 1; MRP 1; NSAIDs; QRT PCR

Indexed keywords

DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; SULINDAC;

ARTICLE; CANCER CELL; CYTOTOXICITY; FEMALE; FLUOROMETRY; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANT TUBERCULOSIS; NICK END LABELING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA;

APOPTOSIS; CYCLOOXYGENASE INHIBITORS; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; IN SITU NICK-END LABELING; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULINDAC; TETRAZOLIUM SALTS; THIAZOLES; UTERINE CERVICAL NEOPLASMS;

EID: 75149166993     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Zatelli MC, Luchin A, Piccin D et al: Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metabol, 2005; 90: 5754-60
2. O'Connor R, Heenan M, Connolly L et al: Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res, 2004; 24: 457-64
3. Patel VA, Dunn MJ, Sorokin A: Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem, 2002; 277: 38915-20
4. Pope JE, McCrea K, Stevens A et al: The relationship between NSAIDs use and osteoarthritis (OA) severity in patients with hip and knee OA: Results of a case control study of NSAIDs use comparing those requiring hip and knee replacements to those in whom surgery was not recommended. Med Sci Monit, 2008; 14(12): CR604-10
5. Kang H-K, Lee E, Pyo H, Lim S-J: Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther, 2005; 4: 1358-63
6. Zalewska R, Zalewski B, Reszec J et al: The expressions of Fas and caspase-3 in human glaucomatous optic nerve axons. Med Sci Monit, 2008; 14(12): BR274-278
7. Baek S J, Wilson L C, Lee Ch-H, Eling TE: Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther, 2002; 301: 1126-31
8. Zhang T, Fields JZ, Ehrlich SM, Boman BM: The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells J Pharmacol Exp Ther, 2004; 308: 434-37
9. Puhlmann U, Ziemann Ch, Ruedell G et al: Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther, 2005; 312: 346-54
10. de Groot D J, Timmer T, Spierings DC et al: Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells. Br J Cancer, 2005; 92: 1459-66
11. Gruber BM, Anuszewska EL: Influence of vitamin D3 metabolites on cell proliferation and cytotoxicity of adriamycin in human normal ad neoplastic cells. Toxicol in Vitro, 2002; 16: 663-67
12. Nakajima-Iijima S, Hamada H, Redy P, Kakunaga T: Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns. PNAS, 1985; 82: 6133-37
13. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) method. Methods, 2001; 25: 402-8
14. Butin SA: Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol, 2005; 25: 169-93
15. Tegeder I, Pfeilschifter J, Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J, 2001; 15: 2057-72
16. Wu YL, Sun B, Zhang XJ et al: Growth inhibition and apoptosis induction of sulindac on human gastric cancer cells. World J Gastroenterol, 2001; 7: 796-800
17. Duffy CP, Elliott CJ, O'Connor RA et al: Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of nonsteroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer, 1998; 34: 1250-59
18. Fantappie O, Solazzo M, Lasagna N et al: P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res, 2007; 67: 4915-23
19. Roller A, Bähr O R, Streffer J et al: Selective potentiation of drug cytotoxicity by NSAIDs in human glioma cells: the role of COX-1 and MRP. Biochem Biophys Res Commun, 1999; 259: 600-5
20. Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S et al: Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells. Arch Pharm Res, 2006; 29: 866-73
21. Matsunaga S, Asano T, Tsutsuda-Asano A, Fukunaga Y: Indomethacin overcomes doxorubicin resistance with inhibiting multi-drug resistance protein 1 (MRP1). Cancer Chemother Pharmacol, 2006; 58: 348-53
22. Draper M P, Martell RL, Levy SB: Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and urine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer, 1997; 75: 810-15